Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1988-2-12
|
pubmed:abstractText |
This single-blind, placebo-controlled study evaluated long-term therapy with cibenzoline in 19 patients with chronic ventricular arrhythmias. Antiarrhythmic efficacy, defined as greater than or equal to 75% reduction in single premature ventricular complexes (PVCs), greater than or equal to 90% reduction in paired PVCs, and total abolition of ventricular tachycardia (VT), was established after dose titration in 14 of 19 (74%) patients. Mean frequency of single PVCs was reduced by 65%, mean paired PVC frequency was reduced by 68%, and mean VT event frequency was reduced by 82%. Antiarrhythmic efficacy was maintained during long-term therapy in five of the 14 (36%) short-term responders. Of the nine patients who discontinued cibenzoline during long-term follow-up, five had a loss of arrhythmia control, three failed to redevelop arrhythmias during placebo reintroduction, and one developed an adverse reaction. Three patients (16%) experienced a proarrhythmic effect. Echocardiographic evaluation did not reveal any deleterious effect of cibenzoline on left ventricular function in the group as a whole. In six patients with preexisting left ventricular dysfunction, left ventricular ejection fraction and fractional shortening improved significantly (P less than .05) during cibenzoline therapy. Adverse effects occurred in seven patients (37%) but necessitated drug discontinuation in only one patient (5%). Cibenzoline provides effective short-term therapy for patients with chronic ventricular arrhythmias. Long-term therapy must be assessed periodically to ensure continued efficacy. Drug-related adverse effects occur infrequently. Cibenzoline can be used safely in patients with compensated left ventricular dysfunction.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0091-2700
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
400-6
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3693585-Adult,
pubmed-meshheading:3693585-Aged,
pubmed-meshheading:3693585-Aged, 80 and over,
pubmed-meshheading:3693585-Anti-Arrhythmia Agents,
pubmed-meshheading:3693585-Arrhythmias, Cardiac,
pubmed-meshheading:3693585-Echocardiography,
pubmed-meshheading:3693585-Electrocardiography,
pubmed-meshheading:3693585-Female,
pubmed-meshheading:3693585-Humans,
pubmed-meshheading:3693585-Imidazoles,
pubmed-meshheading:3693585-Male,
pubmed-meshheading:3693585-Middle Aged
|
pubmed:articleTitle |
Long-term antiarrhythmic therapy with cibenzoline.
|
pubmed:affiliation |
Drug Evaluation Unit, Creighton University School of Medicine, Omaha, NE 68131.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|